Page last updated: 2024-12-07

4-hydroxymephenytoin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxymephenytoin is a chiral drug that is metabolized by the cytochrome P450 enzyme CYP2C19. The S-enantiomer of 4-hydroxymephenytoin is a poor substrate for CYP2C19, while the R-enantiomer is a good substrate. This difference in metabolism is due to the different stereochemical configurations of the two enantiomers. The R-enantiomer of 4-hydroxymephenytoin is a potent inhibitor of CYP2C19, while the S-enantiomer is not. This difference in inhibition is also due to the different stereochemical configurations of the two enantiomers. The R-enantiomer of 4-hydroxymephenytoin has been shown to be a useful tool for studying the function of CYP2C19, while the S-enantiomer is not. 4-hydroxymephenytoin is a useful probe drug for the study of CYP2C19 polymorphisms and the impact of genetic variation on drug metabolism. This is because it exhibits a large interindividual variability in its metabolism due to the polymorphism of CYP2C19. The metabolism of 4-hydroxymephenytoin is therefore a clinically important factor in the pharmacokinetics of drugs metabolized by CYP2C19. The 4-hydroxymephenytoin test is a common genetic test used to determine the activity of CYP2C19.'

4-hydroxymephenytoin: metabolite of mephenytoin; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119507
CHEMBL ID1314943
CHEBI ID166516
MeSH IDM0085356

Synonyms (32)

Synonym
AC-15965
5-ethyl-5-(4-hydroxyphenyl)-3-methylimidazolidine-2,4-dione
CHEBI:166516
hydroxymephenytoin
4-hydroxymephenytoin
NCGC00165917-01
para-hydroxymephenytoin
61837-65-8
4-hydroxymephenytoin, >=98% (hplc)
FT-0669730
4-hydroxy mephenytoin
5-ethyl-5-(4-hydroxyphenyl)-3-methyl-2,4-imidazolidinedione
2,4-imidazolidinedione, 5-ethyl-5-(4-hydroxyphenyl)-3-methyl-
AKOS015962177
FT-0604484
S10420
(+/-)-4-hydroxy mephenytoin
CHEMBL1314943
mfcd00142316
(+/-)-5-ethyl-5-(4-hydroxyphenyl)-3-methylhydantoin
s-4-hydroxymephenytoin
us9333197, 4-hydroxymephenytoin
bdbm224814
BCP17602
SY129593
(+/-)-4'-hydroxymephenytoin
CS-W009488
HY-W008772
5-ethyl-2-hydroxy-5-(4-hydroxyphenyl)-3-methyl-3,5-dihydro-4h-imidazol-4-one
DTXSID20977407
MS-23350
(+/-)4-hydroxymephenytoin

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The plasma half-life of diazepam in the poor metabolizers was longer than that in the extensive metabolizers (mean +/- SEM, 91."( Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
Chiba, K; Ishizaki, T; Jang, IJ; Kusaka, M; Shin, JG; Shin, SG; Sohn, DR, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Daily dosing with 600 mg rifampicin for 22 days caused a three to eightfold increase in the 0-8 h urinary R/S ratio of mephenytoin following oral administration (100 mg) of racemic drug to extensive metabolizers of the anticonvulsant."( Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin.
Anthony, LB; Wilkinson, GR; Wood, AJ; Zhou, HH, 1990
)
0.28
"The ability of normal subjects to hydroxylate mephenytoin (100 mg) or debrisoquine (10 mg) after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee."( Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Aslanian, WS; Branch, RA; McAllister, CB; Wedlund, PJ; Wilkinson, GR, 1984
)
0.27
" As a consequence, alteration in metabolism of specific drugs cannot be easily predicted or appropriate dosage adjustment recommendations made."( Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin, A; Arns, PA; Branch, RA; Richards, WO; Wilkinson, GR, 1998
)
0.3
" They suggest that recommendations for modification in drug dosage in the presence of liver disease should be based on knowledge of the particular enzyme involved in metabolism of the drug."( Selective effect of liver disease on the activities of specific metabolizing enzymes: investigation of cytochromes P450 2C19 and 2D6.
Adedoyin, A; Arns, PA; Branch, RA; Richards, WO; Wilkinson, GR, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolidine-2,4-dioneAn imidazolidinone with oxo groups at position 2 and 4.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency8.91250.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (12.12)18.7374
1990's19 (57.58)18.2507
2000's10 (30.30)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.41 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (13.89%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (86.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]